Stay updated with breaking news from Intelligent Discovery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Veracyte, Inc. announced new research findings suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease. The findings,...
Veracyte, Inc. , a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance for prostate...
Researchers have found that genomic risk distribution can vary widely across clinical stage groups among patients with prostate cancer. Researchers have found that genomic risk distribution can vary widely across clinical stage groups among patients with prostate cancer.
Studies presented at SUO 2023 have shed new light on risk stratification and novel treatments in prostate cancer. Studies presented at SUO 2023 have shed new light on risk stratification and novel treatments in prostate cancer.
Researchers have found that genomic risk distribution can vary widely across clinical stage groups among patients with prostate cancer. Researchers have found that genomic risk distribution can vary widely across clinical stage groups among patients with prostate cancer.